The kinase AKT has been regarded as an obligate intermediate in the insulin signaling pathway that suppresses glucose production by inhibiting the transcription factor forkhead box O1 (FoxO1) after meals. A new study shows that, without AKT-FoxO1 signaling, insulin still contributes to postprandial responses, revealing an AKT-independent pathway for insulin action that might be exploited to treat metabolic disease (pages 388-395).
driver of the transition from fasting to feeding (known as the postprandial transition) 8 because the TLKO mice display an appropriate response to feeding and to insulin itself. Both the expression of gluco neogenic genes and the hepatic production of glucose in the TLKO mice were significantly suppressed by feeding or by insulin treatment. Lu et al. 8 argue convincingly that the major role of hepatic AKT is to suppress FoxO1 after feeding and even partially suppress it in the fasting state. However, to explain how FoxO1 deletion restored insulin sensitivity in TLKO mice, the authors propose that a 'non-canonical' insulin signaling cascade exists, which is suppressed by activated FoxO1 in DLKO mice but which is restored upon FoxO1 deletion and sensitive to insulin in TLKO mice (Fig. 1b) 8 .
It is tempting to speculate that a noncanonical insulin signaling cascade exists, although the nature of this hypothetical pathway is unknown. To narrow down the point at which the non-canonical and canonical pathways diverge, it might be informative to compare the results from the TLKO mice studied by Lu et al. 8 with those obtained from previous experiments with liver-specific Irs1, Irs2 and FoxO1 triple knockout (LTKO IRS ) mice 5 . In contrast to the TLKO mice, which were insulin responsive 8 , LTKO IRS mice had persistent insulin resistance compared to control mice 5 , suggesting that the non-canonical pathway also requires the IRS branch of insulin signaling. As such, the divergent point of the two pathways could reside between IRS and AKT (Fig. 1b,c) . Atypical protein kinase C (aPKCλ) is a potential candidate that could be involved in the non-canonical pathway. aPKCλ can be activated in liver by the IRS-PI3K-PDPK1 cascade and, independently of AKT, phosphorylates CBP to Insulin is the primary hormone controlling systemic nutrient and metabolic homeostasis in mammals. Insulin regulates many anabolic functions, including the stimulation of protein and glycogen synthesis (in muscle and liver), lipid synthesis and storage (in liver and adipose tissue) and the inhibition of fatty acid oxidation, glycogenolysis, gluconeo genesis and autophagy 1 . Insulin resistance leads to hyperglycemia, the hallmark of type 2 diabetes, owing at least in part to persistent hepatic glucose production 2 . Scientists and clinicians have sought for decades to understand what goes wrong with the insulin signaling cascade, with the hope of developing rational strategies to cure metabolic disease and prevent its progression to type 2 diabetes.
The evidence from previous studies converges on a 'canonical pathway' that mediates insulin action in all tissues, including the liver. This pathway begins when insulin activates the transmembrane insulin receptor (IR) tyrosine kinase that phosphorylates the adaptor proteins insulin receptor substrate 1 (IRS1) and IRS2. Once activated by insulin receptor-mediated phosphorylation, the IRS proteins stimulate the class 1A phosphotidylinositol 3-kinase (PI3K) to generate phosphatidyl inositol (3,4,5)-triphosphate (PIP 3 ), which rec ruits 3-phospho inositide dependent protein kinase-1 (PDPK1) and AKT to the plasma membrane, where AKT is activated by PDPK1-mediated phosphorylation 1, 3 . During fasting, dephosphorylated FoxO1-together with a complex of cAMP response element-binding protein (CREB), CREB regulated transcription coactivator 2 (CRTC2) and CREB binding protein (CBP)-upregulates gluconeogenic genes, such as those that encode phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, catalytic subunit (G6Pase). After a meal, insulin-stimulated AKT phosphorylates FoxO1 directly and CRTC2 indirectly to suppress gluconeogenesis (Fig. 1a) 1, 4 .
Recently, emerging evidence from genetically engineered mice has placed the AKTFoxO1 cascade at the center stage of hepatic insulin signaling. Genetic ablation of insulin receptor or IRS uncouples insulin from AKT, locking FoxO1 in its active state and leading to the dysregulated expression of a wide array of genes, including the increased expression of gluconeogenic genes 5, 6 . Remarkably, deletion of hepatic FoxO1 largely normalizes the gene expression 5, 6 . In addition, use of antisense oligo nucleotides to suppress FoxO1 lowers the concentration of circulating glucose and the rate of basal glucose production in insulin-resistant or diabetic subjects 7 , suggesting that the canonical insulin receptor-IRS-PI3K-AKT-FoxO1 cascade is the principal mechanism regulating hepatic glucose production (Fig. 1a) . This 'linear' model of insulin action gains more traction in this issue of Nature Medicine, in which Lu et al. 8 show that systemic glucose intolerance and dysregulated hepatic transcriptional responses caused by the compound deletion of Akt1 and Akt2 (termed there DLKO) in mouse liver are completely normalized by concomitant deletion of hepatic FoxO1.
However, additional experiments with liver-specific Akt1, Akt2 and FoxO1 triple knockout (TLKO) mice suggested that the Akt-FoxO1 cascade might not be the only npg volume 18 | number 3 | mArCH 2012 nature medicine disrupt the CREB-CBP-CRTC2 complex and suppress peroxisome proliferator-activated receptor-γ co-activator 1α (Ppargc1α), a key component for FoxO1-mediated and CREB-mediated gluconeogenesis 4, 9, 10 . Indeed, Ppargc1α expression is significantly reduced by feeding in DLKO and TLKO mice 8 but not in Irs1 and Irs2 double knockout (LDKO IRS ) and LTKO IRS mice that lack IRS-PI3K-PDPK1 signaling 5 . Thus, the PDPK1-aPKCλ branch of the canonical pathway could account, at least in part, for the non-canonical pathway proposed by Lu et al. 8 (Fig. 1c) .
Whereas FoxO1 could mediate the postprandial response through a non-canonical insulin signaling pathway, it might also contribute to the fasting-feeding transition by modulating key cellular functions. Persistent FoxO1 activity can dysregulate mitochondrial function and oxidative capacity, which changes the ratios of NAD + to NADH and AMP to ATP in the liver 11, 12 . These changes can dysregulate other energy and nutrient sensors, such as sirtuin 1 (Sirt1) or AMP-activated protein kinase (AMPK), that also control gluconeogenesis 4, 9, 11 . Further study to dissect the molecular links between these regulators might help to delineate a FoxO1-mediated non-canonical insulin signaling pathway.
Regardless, the findings from TLKO mice by Lu et al. 8 After feeding, insulin receptor-IRS-PI3K-PDPK1-AKT signaling is stimulated (green), which phosphorylates and inactivates FoxO1 and the CREB-CBP-CRTC2 complex, thus suppressing the expression of gluconeogenic genes (encoding PEPCK and G6Pase) (gray). During fasting, insulin receptor-IRS-PI3K-PDPK1-AKT signaling is less active than in feeding (gray), thus turning on the activities of FoxO1, the CREB-CBP-CRTC2 complex and gluconeogenesis (green). The P in the yellow circles denotes activating phosphorylation, and the P in the red circles denotes inhibitory phosphorylation. (b) Lu et al. 8 suggest the existence of a hypothetical noncanonical pathway by which insulin controls gluconeogenesis. They suggest that the noncanonical pathway, which has yet to be identified, suppresses gluconeogenesis in parallel with the canonical pathway during feeding; however, activated FoxO1 during fasting or insulin resistance dampens the non-canonical pathway and stimulates the expression of gluconeogenic genes and glucose production. A comparison of TLKO mice and LTKO IRS mice implied that the divergent point of the non-canonical pathway from the canonical pathway could reside between IRS and AKT. (c) The PDPK1-aPKCλ signaling cascade may be a potential candidate accounting for the non-canonical pathway. In response to insulin or stimuli after feeding, insulin receptor-IRS-PI3K-PDPK1 signaling activates aPKCλ, which, in turn, phosphorylates CBP and disrupts the CREB-CBP-CRTC2 complex and suppresses gluconeogenesis. However, in DLKO or TLKO mice, this pathway could remain active and contribute to the postprandial response. npg issues will be important because humans with AKT2 defects manifest hypertriglyceridemia and hepatic steatosis in addition to insulin resistance and hyperglycemia 14, 15 . Whether the hepatic steatosis in the face of hyperglycemia implies a role for a non-canonical insulin signaling pathway during compensatory hyper insulinemia is unknown and is worthy of further investigation.
LTKO IRS mice 5 strongly suggest that inhibition of hepatic FoxO1 might be a promising strategy to reverse features of the metabolic syndrome, such as hyperglycemia and hyperinsulinemia. Particularly, ablation of FoxO1 results in a more comprehensive restoration of metabolic homeostasis in Akt-deficient mice 8 than in Irs-deficient mice 5 , including a restoration of insulin sensiti vity. However, lipid metabolism in DLKO mice and the effects of FoxO1 ablation have not been characterized 8 , and the uncoupled regulation of lipogenesis and gluconeogenesis by insulin resistance is not completely understood 3, 13 . Resolving these
The quest for human ovarian stem cells
Researchers have isolated a rare population of germline stem cells from adult mouse and human ovaries that are capable of forming oocytes. The ability to harvest such cells from human ovaries could change the options available for fertility preservation and the treatment of infertility (pages 413-421).
In most mammalian females, the ovaries undergo age-related dysfunction and failure, and it has long been believed that this occurs as a consequence of the depletion of a nonrenewable pool of female germ cells (primordial follicles) established before (or shortly after) birth. This cornerstone of mammalian female reproductive biology was challenged by a study published 8 years ago suggesting that the mouse ovary retained the capacity to produce germ cells throughout life 1 . However, the isolation and identification of oocyteproducing germ line stem cells, also called oogonial stem cells (OSC), as unequivocal proof of their existence in the ovaries of adult mammals in general, and of humans in particular, remained elusive. In this issue of Nature Medicine, White et al. 2 report the isolation of cells from both mouse and human ovary that are capable of forming oocyte-like structures and that become incorporated into follicles under specific in vitro and in vivo conditions 2 . The isolation of such rare cells from adult human ovaries has crucial biological relevance and may have important clinical implications. The ability to isolate and store OSCs that are capable of producing functional oocytes would have a major impact on the fertility preservation options available for individuals receiving gonadotoxic therapies for cancer treatment and women with primary ovarian insufficiency.
The existence and physiological role of mammalian female germline stem cells has historically been highly contentious 3, 4 . The mammalian ovary is a dynamic and regenerative organ during the reproductive lifespan of mammals. In women, substantial ovarian tissue remodeling occurs each menstrual cycle, requiring the replenishment and turnover of many different somatic cell types. In contrast, it has generally been accepted that the oocyte population is finite (with approximately 1 million follicles being present at birth) and is incapable of de novo restoration 5 . Indeed, the question of why age-related ovarian failure and menopause occur originates in the belief that mammalian females are unable to replenish their oocyte reserve, leading to a progressive and irreversible decline in follicle numbers until the pool is exhausted late in adult life 5 .
Previous studies hinting at the presence of OSCs in adult mice 6 relied on magnetic cell sorting to extract putative germ-cell progenitors from dissociated ovaries using an antibody presumed to recognize only germ cells.
Because the antibody targeted the C terminus of the mouse vasa homolog (Mvh) (herein referred to as DEAD box polypeptide 4 or Ddx4, a germ-cell-specific RNA helicase), this study prompted criticism as a result of methodological inconsistencies within the studies 7 . For example, because DDX4 (MVH) is intracellular, the antibody in question could not have selected for germ cells based on cell-surface sorting, leading to suggestions that cells damaged in the process of isolation released intracellular protein that nonspecifically affixed to other cells. This controversy served as a point of departure for the present studies by White et al. 2 .
Resolving this problem required a deeper understanding of DDX4 disposition on germ cells, the use of a distinct antibody to the N terminus of a cell-surface form of DDX4 and the adoption of fluorescence-activated cell sorting (FACS) methods rather than the magnetic-bead-based strategy used in the earlier work 6 . Although both the N and C termini antibodies recognized germ cells by immunohistochemistry in ovarian sections, only the N terminus-specific antibody was able to extract viable germ cells when FACS was used.
Armed with a measureable improvement in technology, the new study goes on to provide evidence consistent with the existence of a population of cells within adult human and mouse ovaries that can be propagated in vitro 2 . Moreover, after mitotic amplification,
